Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01758731 · ClinicalTrials.gov registry record · Phase 1
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01758731 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 17 participants.
The verdict
NCT01758731, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a research study that plans to learn more about the safety and tolerability of an investigational drug called Olaparib, in combination with radiation therapy and cetuximab. Hypothesis: Intensity modulated radiotherapy with concurrent C225 and Olaparib represents a feasible, biologically-based alternative to standard chemoradiation, with acceptable toxicity, for treatment of locally-advanced HNSCC in patients having a ≥ 10 pack-year smoking history.
Interventions
- DRUG Olaparib
- RADIATION Radiation Therapy
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-10-22 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01758731
The ClinicalTrials.gov registry entry for NCT01758731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Olaparib is the first listed.
NCT01758731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01758731 about?
NCT01758731 is a clinical study titled "Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History". This is a research study that plans to learn more about the safety and tolerability of an investigational drug called Olaparib, in combination with radiation therapy and cetuximab. Hypothesis: Intensity modulated radiotherapy with concurrent C225 and Olaparib represents a feasible, biologically-bas...
What is the current status of trial NCT01758731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-10-22. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT01758731?
The interventions under investigation include: Olaparib (DRUG), Radiation Therapy (RADIATION), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01758731?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.